Nanobiotix S.A.
NASDAQ:NBTXBiotechnology
Healthcare
$27.32 -0.91%
-$0.33 today
- Market cap
- $1.39B
- Beta
- 0.59
- P/E (TTM)
- -60.2
- EPS (TTM)
- -$0.51
52W Low $4.31High $57.14
Volume 0.18M
Average 0.08M
Income Statement
Follow revenue through to earnings.
Revenue
$29.64M
FY 2025 · Annual
Operating Income
-$10.82M
FY 2025 · Annual
Net Income
-$23.96M
FY 2025 · Annual
Income Statement
EUR
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.65M | 4.78M | 36.21M | (7.19M) | 29.64M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 2.65M | 4.78M | 36.21M | (7.19M) | 29.64M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 30.38M | 32.64M | 38.4M | 40.54M | 23.12M |
| Selling, General & Admin | 19.43M | 17.86M | 22.05M | 20.53M | 20.22M |
| Operating Expenses | 55.23M | 51.48M | 62.99M | 61.2M | 40.46M |
| Depreciation & Amortization | 1.56M | 1.5M | 551K | 592K | 1.5M |
| EBITDA | (45.61M) | (44.22M) | (23.69M) | (67.67M) | (12.07M) |
| EBITDA Margin | -1722.9% | -925.8% | -65.4% | 941.1% | -40.7% |
| Operating Income | (52.58M) | (46.7M) | (26.78M) | (68.39M) | (10.82M) |
| Operating Margin | -1986.4% | -977.8% | -74.0% | 951.2% | -36.5% |
| Interest Income | 0 | 256K | 1.22M | 2.63M | 985K |
| Interest Expense | 699.49K | 5.84M | 7.98M | 8.09M | 10.4M |
| Other Income / Expenses | 5.58M | (10.33M) | (12.8M) | 361K | (13.14M) |
| Income Before Tax | (47M) | (57.03M) | (39.58M) | (68.03M) | (23.96M) |
| Pre-Tax Margin | -1775.5% | -1194.1% | -109.3% | 946.2% | -80.8% |
| Income Tax Expense | 5K | 10K | 120K | 101K | 3K |
| Net Income | (47M) | (57.04M) | (39.7M) | (68.13M) | (23.96M) |
| Net Margin | -1775.7% | -1194.3% | -109.6% | 947.6% | -80.8% |
| EPS (Basic) | (1.35) | (1.64) | (1.08) | (1.44) | (0.50) |
| EPS (Diluted) | (1.35) | (1.64) | (1.08) | (1.44) | (0.50) |
| 34.73M | 34.85M | 36.76M | 47.27M | 47.82M | |
| 34.73M | 34.85M | 36.93M | 47.27M | 47.82M |
NBTX Earnings Waterfall · TTM
NASDAQ:NBTX · Revenue to Net Income
Key Ratios
EPS$-1.94
Gross Margin100.0%
Net Margin-148.3%
P/E Ratio-6.2
P/S Ratio84.4
Analysis
$22.5M of revenue converted into -$92.1M of net income for the selected period. Gross margin is 100.0% and net margin is -148.3%, showing how much revenue survives after costs and taxes. EPS is $-1.94, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 12, 2026 | |
| 6-K | 6-K filing | Nov 9, 2026 | |
| 6-K | 6-K filing | Oct 26, 2026 | |
| 6-K | 6-K filing | Oct 20, 2026 | |
| 6-K | 6-K filing | Oct 1, 2026 |
How much revenue does NBTX generate?
Nanobiotix S.A. (NBTX) reported $29.64M of revenue in fiscal 2025.
Is NBTX profitable?
Nanobiotix S.A. (NBTX) reported -$23.96M of net income, with a net margin of -80.8%.
Continue the stock analysis
Jump to another research area for this company.